<?xml version="1.0" encoding="UTF-8"?>
<p>Antimicrobial evaluation against one human pathogen 
 <italic>Escherichia coli</italic> EMBLC-1 (EC), 10 marine-derived quatic bacteria 
 <italic>Aeromonas hydrophilia</italic> QDIO-1 (AH), 
 <italic>Edwardsiella tarda</italic> QDIO-2 (ET), 
 <italic>E. ictarda</italic> QDIO-10, 
 <italic>Micrococcus luteus</italic> QDIO-3 (ML), 
 <italic>Pseudomonas aeruginosa</italic> QDIO-4 (PA), 
 <italic>Vibrio alginolyticus</italic> QDIO-5, 
 <italic>V. anguillarum</italic> QDIO-6 (VAn), 
 <italic>V. harveyi</italic> QDIO-7 (VH), 
 <italic>V. parahemolyticus</italic> QDIO-8 (VP), and 
 <italic>V. vulnificus</italic> QDIO-9 (VV), was carried out by the microplate assay. Compound 
 <bold>50</bold> showed activity with the same MIC value of 8 µg/mL against 4 bacteria ((EC) (AH) (PA) and (VH)) and the value of 4 µg/mL against 
 <italic>V. parahemolyticus</italic>. Compound 
 <bold>51</bold> showed activity with the MIC values of 16 µg/mL (EC), 8 µg/mL (PA) and 16 µg/mL (VH). Compound 
 <bold>52</bold> showed activity with the MIC values of 8 µg/mL (EC), 8 µg/mL (AH), 4 µg/mL (PA), 2 µg/mL (VH) and 8 µg/mL (VP). While compound 
 <bold>55</bold> had activity against aquatic pathogens 
 <italic>Edwardsiella tarda</italic> and 
 <italic>Vibrio anguillarum</italic> with MIC values of 1 μg/mL and 2 μg/mL, respectively, comparable to that of the positive control chloramphenicol (2 µg/mL (EC), 4 µg/mL (AH), 0.5 µg/mL (ET), 4 µg/mL (ML), 2 µg/mL (PA), 1 µg/mL (VAn), 1 µg/mL (VH), 4 µg/mL (VP), 1 µg/mL (VV)) [
 <xref rid="B25-ijms-22-00959" ref-type="bibr">25</xref>].
</p>
